Chris Sheldon - AstraZeneca PLC Head Relations

ZEGA Stock  EUR 63.50  1.00  1.60%   

Insider

Chris Sheldon is Head Relations of AstraZeneca PLC
Phone44 20 3749 5000
Webhttps://www.astrazeneca.com

AstraZeneca PLC Management Efficiency

The company has return on total asset (ROA) of 0.0555 % which means that it generated a profit of $0.0555 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0863 %, meaning that it generated $0.0863 on every $100 dollars invested by stockholders. AstraZeneca PLC's management efficiency ratios could be used to measure how well AstraZeneca PLC manages its routine affairs as well as how well it operates its assets and liabilities.
AstraZeneca PLC has accumulated 22.96 B in total debt with debt to equity ratio (D/E) of 144.4, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. AstraZeneca PLC has a current ratio of 0.93, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist AstraZeneca PLC until it has trouble settling it off, either with new capital or with free cash flow. So, AstraZeneca PLC's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like AstraZeneca PLC sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for AstraZeneca to invest in growth at high rates of return. When we think about AstraZeneca PLC's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Jennifer DamicoPfizer Inc
55
Norman FitzgeraldNMI Holdings
56
Michael TrimbleOrigin Agritech
56
Robert GreenSIVERS SEMICONDUCTORS AB
60
Thomas HudsonAbbVie Inc
61
Christopher CFAPfizer Inc
N/A
Robert SmithNMI Holdings
53
Jan WickeTalanx AG
55
Caroline SchlienkampTalanx AG
49
Larry CordellOrigin Agritech
56
JeanJacques HenchozTalanx AG
59
Steven HumphreysIdentiv
62
Edward KirnbauerIdentiv
58
Mohammad YousafNMI Holdings
47
Ravi MallelaNMI Holdings
53
Elizabeth SheaAbbVie Inc
N/A
Manfred MuellerIdentiv
53
Scott ReentsAbbVie Inc
56
Erik WiklundSIVERS SEMICONDUCTORS AB
49
Edgar PulsTalanx AG
50
Sven PetterssonSIVERS SEMICONDUCTORS AB
60
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom. ASTRAZENECA operates under Drug Manufacturers - Major classification in Germany and is traded on Frankfurt Stock Exchange. It employs 64400 people. AstraZeneca PLC (ZEGA) is traded on Frankfurt Exchange in Germany and employs 83,500 people.

Management Performance

AstraZeneca PLC Leadership Team

Elected by the shareholders, the AstraZeneca PLC's board of directors comprises two types of representatives: AstraZeneca PLC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AstraZeneca. The board's role is to monitor AstraZeneca PLC's management team and ensure that shareholders' interests are well served. AstraZeneca PLC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AstraZeneca PLC's outside directors are responsible for providing unbiased perspectives on the board's policies.
Marc Dunoyer, CEO Officer
Chris Sheldon, Head Relations
Pam Cheng, EVP Board
MBA DVM, CEO Director
Gonzalo Vina, Head Relations
Aradhana MD, CFO Director
Menelas Pangalos, EVP Board
Katarina Ageborg, Chief Sustainability
Jeffrey Pott, G Officer
Ruud Dobber, Exec Unit

AstraZeneca Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is AstraZeneca PLC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Other Information on Investing in AstraZeneca Stock

AstraZeneca PLC financial ratios help investors to determine whether AstraZeneca Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in AstraZeneca with respect to the benefits of owning AstraZeneca PLC security.